By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news originating from Padova, Italy, by NewsRx correspondents, research stated, "Triple-negative breast cancer (TNBC), that is breast cancer which stains negatively at immunohistochemistry for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 2 (HER2), comprises a particularly aggressive subtype of breast cancer, with high rate of early local and distant relapse. TNBC have demonstrated sensitivity to cytotoxic treatment regimens, but in the absence of HER2, ER and PR there is no benefit from hormonal therapy or trastuzumab."
Our news journalists obtained a quote from the research from Institute for Cancer Research and Treatment (IRCCS), "The lack of known specific molecular targets has promoted abundant research in order to find possible 'vulnerabilities' in TNBC and the evaluation of novel biomarkers overcoming the traditional approach based on hormonal receptors and HER2-targeted therapy is one of the priorities in breast cancer research. Drugs under investigation can be broadly subdivided into four groups: (1) Agents that create DNA damage (i.e. cisplatin, cyclophosphamide); (2) Agents that inhibit poly (ADP-ribose) polymerase (PARP); (3) Tyrosin-kinase inhibitors and monoclonal antibodies; (4) Agents that inhibit downstream signals. Several preclinical and early phase clinical trials for the treatment or management of patients with triple-negative breast tumors are underway. Nonetheless, so far the major issue to deal with when trying to provide evidence for TNBC is the small numbers of the sample in the clinical studies and the retrospective nature of most of them."
According to the news editors, the research concluded: "Future large studies could help in defining optimal treatment strategies for TNBC, both in the advanced setting as well as in the (neo) adjuvant setting."
For more information on this research see: Targeted approaches to triple-negative breast cancer: current practice and future directions. Current Medicinal Chemistry, 2013;20(5):605-12. (Bentham Science Publishers - www.benthamscience.com; Current Medicinal Chemistry - www.benthamscience.com/cmc/index.htm)
The news correspondents report that additional information may be obtained from A. Brunello, Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy. Additional authors for this research include L. Borgato, U. Basso, F. Lumachi and V. Zagonel (see also Biotechnology).
Keywords for this news article include: Biotechnology, Italy, Padova, Europe, Oncology, Treatment, Cancer Gene Therapy, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC